Table of Contents
Chapter - 1
- INTRODUCTION
- 1.1. The Immune System
- 1.2. Scope of This Report
Chapter - 2
- MAJOR CANCERS AND INFECTIOUS DISEASES TARGETED BY NEW AND/OR EMERGING
IMMUNOTHERAPIES AND VACCINES TO ENHANCE THE IMMUNE SYSTEM
- 2.1. Major Cancers Targeted by Immunotherapies and Vaccines
- Brain Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Leukemia
- Lung Cancer
- Non - Small-Cell Lung Cancer
- Small-Cell Lung Cancer
- Lymphoma (Non - Hodgkin' s Lymphoma)
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cancer
- 2.2. Major Infectious Diseases Targeted by Emerging Immunotherapies and
Vaccines
- Anthrax
- Campylobacter
- Cytomegalovirus
- Dengue
- Diphtheria
- Encephalitis
- Haemophilus influenzae Type b
- Hepatitis B Virus
- Hepatitis C Virus
- Herpes Simplex Virus
- Human Immunodeficiency Virus
- Human Papillomavirus
- Influenza
- Malaria
- Meningococcal Disease; Neisseria meningitidis
- Pertussis
- Pneumococcal Disease; Streptococcus pneumoniae
- Polio (Poliomyelitis)
- Respiratory Syncytial Virus
- Tetanus
- Tuberculosis
- West Nile Virus
Chapter - 3
- CURRENT PHARMACOLOGICAL OPTIONS FOR TREATMENT AND PREVENTION OF CANCER,
AND IMMUNOTHERAPY/VACCINE OPTIONS FOR TREATMENT AND PREVENTION OF INFECTIOUS
DISEASES
- 3.1. Current Pharmacological Options for Treatment and Prevention of
Cancer
- Brain Cancer
- Breast Cancer
- Chemotherapy
- Hormone Therapy
- Targeted Therapy: HER2-Positive Cancers
- Targeted Therapy: VEGF and Angiogenesis
- Cervical Cancer
- Colorectal Cancer
- Chemotherapy
- Targeted Therapy: Monoclonal Antibodies
- Leukemia
- Pharmacological Therapies (Chemotherapy and Others)
- Bone Marrow Transplants and Peripheral Stem Cell Transplants
- Lung Cancer
- Chemotherapy (Non - Small-Cell Lung Cancer)
- Targeted Therapy: Kinase Inhibitors (Non - Small-Cell Lung Cancer)
- Targeted Therapy: Monoclonal Antibodies (Non - Small-Cell Lung Cancer)
- Photodynamic Therapy (Non - Small-Cell Lung Cancer)
- Chemotherapy (Small-Cell Lung Cancer)
- Lymphoma (Non - Hodgkin' s Lymphoma)
- Chemotherapy
- Monoclonal Antibodies
- Other Immune-Based Therapies
- Other Targeted Therapies: Histone Deacetylase Inhibitor
- Melanoma
- Interferon
- Interleukin-2
- Chemotherapy
- Ovarian Cancer
- Pancreatic Cancer
- Chemotherapy
- Targeted Therapy: Inhibition of EGFR Tyrosine Kinase
- Prostate Cancer
- Luteinizing Hormone - Releasing Hormone Agonists
- Antiandrogens
- Chemotherapy
- Renal Cancer
- Targeted Therapy: Kinase Inhibitors
- 3.2. Current Infectious Disease Immunotherapies and Vaccines
- Passive Immunotherapy
- Immunotherapy for Treatment of Chronic Infections
- Infectious Disease Vaccines
- 3.3. Medical and Market Needs; R&D Challenges
- Cancer Immunotherapies and Vaccines
- Infectious Disease Immunotherapies and Vaccines
Chapter - 4
- EXAMPLES OF CURRENT AND EMERGING APPROACHES TO ENHANCE THE IMMUNE
SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE
- 4.1. New Approaches for Cancer Immunotherapy and Vaccines
- Nonspecific Active Immunotherapy (Immune-Modulating Agents)
- Antigen Immunotherapies/Vaccines (Allogeneic)
- Autologous Antigen Immunotherapies/Vaccines
- Allogeneic Whole-Tumor-Cell Immunotherapies/Vaccines
- Autologous Whole-Tumor-Cell Immunotherapies/Vaccines
- Dendritic Cell Immunotherapies/Vaccines
- DNA and Viral Vector Vaccines
- 4.2. Infectious Disease Vaccines
- Types of Vaccines
- Adjuvants
Chapter - 5
- CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
- 5.1. Brain Cancer
- Advantagene
- Antisense Pharma
- Celldex Therapeutics
- Merck Serono
- Northwest Biotherapeutics
- 5.2. Breast Cancer
- Antigen Express (Subsidiary of Generex Biotechnology)
- Apthera
- Celldex Therapeutics
- Introgen Therapeutics
- Peregrine Pharmaceuticals
- 5.3. Cervical Cancer
- 5.4. Colorectal Cancer
- Celldex Therapeutics
- GenVec
- immatics biotechnologies
- Oxford BioMedica and sanofi-aventis
- Vaccinogen
- 5.5. Leukemia
- Argos Therapeutics
- Cell Genesys
- Geron
- The Vaccine Company
- 5.6. Lung Cancer
- Agennix
- AVAX Technologies
- GlaxoSmithKline
- GlobeImmune
- IDM Pharma
- Introgen Therapeutics
- Merck Serono and Oncothyreon
- Merck Serono
- NovaRx
- Peregrine Pharmaceuticals
- Pfizer
- Pharmexa
- Transgene
- Vaxon Biotech
- 5.7. Lymphoma (Non - Hodgkin' s Lymphoma)
- Biovest International
- Transgene
- 5.8. Melanoma
- Antigenics
- AVAX Technologies
- BioVex
- GenVec
- GlaxoSmithKline
- Medarex and Bristol-Myers Squibb
- Merck Serono
- Oxford BioMedica
- Sanofi Pasteur
- SciClone Pharmaceuticals and Sigma-Tau
- Vical
- ZymoGenetics
- 5.9. Ovarian Cancer
- AVAX Technologies
- Menarini Group
- 5.10. Pancreatic Cancer
- Celldex Therapeutics
- Cell Genesys
- GenVec
- GlobeImmune
- Lorus Therapeutics and Zor Pharmaceuticals
- Pharmexa
- 5.11. Prostate Cancer
- Advantagene
- Bavarian Nordic
- Cell Genesys
- Dendreon
- Northwest Biotherapeutics
- Onyvax
- Oxford BioMedica and sanofi-aventis
- 5.12. Renal Cancer
- Active Biotech
- Agennix
- Antigenics
- Argos Therapeutics
- Endocyte
- Idera Pharmaceuticals and Merck Serono
- immatics biotechnologies
- LipoNova
- Oxford BioMedica and sanofi-aventis
- ZymoGenetics
- 5.13. Immunotherapies and Vaccines in Development for Other or
Nonspecified Cancer Indications
Chapter - 6
- IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT FOR PREVENTION AND
TREATMENT OF INFECTIOUS DISEASES
- 6.1. Anthrax and Other Biodefense Vaccines
- 6.2. Campylobacter and/or Enterotoxigenic Escherichia coli (Traveler' s
Diarrhea)
- Ace Biosciences
- Intercell
- 6.3. Cytomegalovirus
- 6.4. Dengue
- GlaxoSmith Kline
- Sanofi Pasteur
- 6.5. Encephalitis
- Novartis and Intercell
- Sanofi Pasteur
- 6.6. Hepatitis B
- Emergent BioSolutions
- Merck and Dynavax
- 6.7. Hepatitis C
- GlobeImmune
- Hemispherx Biopharma
- Human Genome Sciences and Novartis
- Novartis Vaccines and Intercell
- SciClone Pharmaceuticals
- 6.8. Herpes Simplex Virus
- 6.9. Human Immunodeficiency Virus (HIV)
- Argos Therapeutics
- Bionor Immuno
- GenVec
- Hemispherx Biopharma
- Sanofi Pasteur
- Targeted Genetics
- 6.10. Human Papillomavirus (HPV)
- GlaxoSmithKline
- Merck
- MGI Pharma (Subsidiary of Eisai)
- Transgene and Roche
- 6.11. Influenza
- Baxter Vaccines
- CSL Biotherapies
- GlaxoSmithKline
- Novartis Vaccines
- Protein Sciences Corporation
- Sanofi Pasteur
- 6.12. Malaria
- 6.13. Meningococcal Disease; Neisseria meningitidis
- 6.14. Pneumococcal Disease; Streptococcus pneumoniae
- 6.15. Respiratory Syncytial Virus
- 6.16. Tuberculosis
- Emergent BioSolutions
- GlaxoSmithKline
- 6.17. West Nile Virus
- 6.18. Emerging Combination Vaccines
- 6.19. Other Emerging Infectious Disease Vaccines
Chapter - 7
- SELECTED BUSINESS CONSIDERATIONS: IMMUNOTHERAPIES AND VACCINES THAT
ENHANCE THE IMMUNE SYSTEM
- 7.1. Companies in the Infectious Disease and Cancer Vaccines and
Immunotherapies Fields
- 7.2. Diseases Targeted for Product Development
- Infectious Disease
- Cancer
- 7.3. Technical Issues and Challenges for Cancer and Infectious Disease
Vaccines and Immunotherapies
- 7.4. Partners (Corporate and Noncorporate) and Acquisitions
- 7.5. Human Papillomavirus - Infectious Disease Prophylactic Vaccine for
Prevention of Cancer: Example of a Controversy with a New Vaccine
- Social Issues
- Safety Issues
Chapter - 8
- EXPERT INTERVIEWS
- Estuardo Aguilar-Cordova, MD, Founder & Chief Executive Officer,
Advantagene, Inc., Waban, MA
- David Apelian, MD, PhD, MBA, Vice President, Clinical Development
and Regulatory Affairs, and Chief Medical Officer, GlobeImmune, Louisville, CO
- Robert Coffin, PhD, Chief Technology Officer, Founder and Director,
BioVex, Woburn, MA
- Raafat E.F. Fahim, PhD, President and Chief Executive Officer, Nabi
Pharmaceuticals, Rockville, MD
- Drew Hannaman, Vice President, Research and Development, Ichor
Medical Systems, San Diego, CA
- Kristen M. Hege, MD, Vice President, Clinical Research and
Development, Cell Genesys, South San Francisco, CA
- Frank Malinoski, MD, PhD, Senior Vice President, Medical and
Scientific Affairs, MedImmune, Gaithersburg, MD
- Cynthia W. Tuthill, PhD, Senior Vice President, Scientific Affairs,
& Chief Scientific Officer, SciClone Pharmaceuticals, Foster City, CA
- Sunny Uberoi, Vice President, Corporate Communications, Antigenics,
New York, NY
References
Company Index with Web Addresses
|
Related Report
|
View Cart
